BLFS
BioLife Solutions·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 5
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
High Cash/net Profit Ratio
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BLFS
Biolife Solutions, Inc.
A leading supplier of class-defining bioproduction tools and services for the cell and gene therapy and broader biopharma markets
Healthcare Technology
--
03/26/2014
NASDAQ Stock Exchange
159
12-31
Common stock
3303 Monte Villa Parkway
, Suite 310
, Bothell
, Washington 98021
--
BioLife Solutions, Inc., founded in 1987, is headquartered in Delaware, USA. The Company is a life science company that develops, manufactures and markets biological production tools and services designed to improve quality and reduce risks in biological manufacturing, storage, distribution and transportation in the cell and gene therapy (" CGT ") industry and the broader biopharmaceutical market. The Company's products are used in the basic and applied research and commercial manufacturing of biological-based therapies. Customers use products to maintain the health and function of biomaterials during procurement, manufacturing, storage and distribution.
Earnings Call
Q1/2025
Estimate EPS-0.04
Actual EPS-0.01
Estimate Revenue22.22M
Actual Revenue23.94M
BioLife's Q1 2025: Navigating Contradictions in NIH Funding, Pricing Strategies, and Tariff Impacts
May 19,2025 05:17
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
BLFS has released its 2025 Q3 earnings. EPS was reported at 0.01, versus the expected 0, beating expectations. The chart below visualizes how BLFS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
BLFS has released its 2025 Q3 earnings report, with revenue of 28.07M, reflecting a YoY change of 31.21%, and net profit of 621.00K, showing a YoY change of 136.47%. The Sankey diagram below clearly presents BLFS's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
